Review of probiotic research finds only Bifantis can claim efficacy vs. placebo for IB...( PHILADELPHIA October 15 2007 A new...),Health
PHILADELPHIA October 15, 2007 A new analysis of randomized controlled trials evaluating probiotics in the treatment of irritable bowel syndrome (IBS) has found that Bifantis, Bifidobacterium infantis 35624, the sole ingredient in Align (manufactured by Procter & Gamble), is the only probiotic currently able to demonstrate significant improvement in IBS symptoms based upon a properly designed research study. Researchers at the University of Michigan conducted the review to evaluate the safety, efficacy and tolerability of probiotics for IBS in randomized controlled trials and found that, with the exception of the Bifidobacterium infantis 35624 studies, most were not designed in a way that made the data possible to validate. The review data were presented this week at the annual American College of Gastroenterology (ACG) conference taking place in Philadelphia, PA.
There is growing interest in medical and patient communities about the use of probiotics in IBS and lots of data has been published about this topic, but its helpful to know the quality of that data before making a treatment decision, said Darren Brenner, MD, lead investigator on this project. Our analysis showed that only this particular strain of probiotic, Bifidobacterium infantis 35624, has valid data for successfully treating IBS symptoms. At this point, we just dont have enough valid data to determine if other probiotics are effective for IBS.
The Study
The goal of this systematic review of randomized controlled trials was to evaluate the efficacy, safety and tolerability of probiotics in the treatment of IBS. Criteria for the study included randomized controlled trials testing adults with IBS symptoms using single or combination probiotics versus placebo for IBS symptoms and frequency of adverse events.
Of the 13 trials that met selection criteria, 11 demonstrated sub-optimal study design with inadequate blinding, inadequate trial length, inadequate sample
'/>"/>
| Contact: Shirley Johnson Shirley.Johnson@mslpr.com Manning Selvage & Lee Source:Eurekalert |
Related medicine news :
1. FDA may speed review of new drugs
2. Scientists review SARS
3. US Reviews Risks Of Tamiflu After 12 Children Die
4. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
5. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
6. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
7. Thumbs up in weight loss for vegetarian diets: scientific review
8. FDA Accords Priority Review For Pediatric Crohns Disease Drug
9. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
10. Review of Pramod Mahajans Injuries
11. Vaticans Council Reviews Condom Usage
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |